Pharmacologic behavior management of pediatric dental patients diagnosed with attention deficit disorder/attention deficit hyperactivity disorder

PURPOSE: The purpose of this study was to conduct a survey of Texas pediatric dentists to determine: (1) the percentage of patients they treat with attention deficit disorder (ADD)/attention deficit hyperactivity disorder (ADHD); (2) the behavior management techniques that are utilized to treat their patients who suffer from ADD/ADHD; and (3) the relative success rates of these techniques in their practices. METHODS: A 17-question, single-answer, multiple choice survey was mailed to 343 Texas pediatric dentists. The mailing list was obtained from American Academy of Pediatric Dentistry and Texas Academy of Pediatric Dentistry member rosters. One mailing was sent, including a self-addressed stomped envelope, for returned responses. RESULTS: A 54% response rate (186 surveys) revealed that nitrous oxide was the most frequently used pharmacologic behavior management technique; however, demerol/promethazine/nitrous oxide was rated as effective most often for treating ADD/ADHD patients. CONCLUSIONS: Practitioners believe the incidence of attention deficit disorder/attention deficit hyperactivity disorder is increasing, and they are familiar with the medications used to treat the conditions. Texas pediatric dentists are using a variety of sedation techniques and are interested in developing guidelines for sedation of these patients.     

The Interaction Between the Indirect Anticoagulant Coumatetralyl and Calciferol (Vitamin D3) in Warfarin-resistant Rats (Rattus norvegicus)

Resistance to 4-hydroxycoumarin anticoagulant rodenticides has been a problem in some local foci for a number of years. One method of managing resistance could be to use synergists in conjunction with anticoagulants. We investigated the effect of administering cholecalciferol and coumatetralyl alone and in a synergistic mixture to anticoagulant-resistant rats by monitoring plasma factor X concentrations. The study showed that the efficacy of the compounds was significantly improved when they were used together. This synergistic effect led to an increased mortality in female rats that had been treated with both compounds compared to both a control group and groups of rats that had received the compounds singly. An unexpected result from this work was that cholecalciferol when given on its own to rats caused a decrease in plasma factor X concentration. We hypothesise that this effect was due to a vitamin D-induced increase in production of vitamin K-dependent proteins leading to a saturation of the carboxylation process and hence to a significant number of factor X molecules being under-carboxylated and therefore dysfunctional. It is suggested that the reduction in factor X levels is a major component of the increased efficacy of the anticoagulant/calciferol mixture and also that effects on other vitamin K-dependent proteins, e.g. matrix GLA protein, may play a role in the increased mortality seen in female rats.  This work illustrates that synergists could be utilised in managing anticoagulant resistance. There are also possible implications for human patients on anticoagulant therapy who may be receiving increased amounts of vitamin D analogues through, for example, dietary supplements.     

Platelet and vascular function during coronary thrombolysis with tissue-type plasminogen activator

Platelet activation may limit the response to tissue-type plasminogen activator (t-PA) during coronary thrombolysis in humans. As an index of platelet activation, we assessed thromboxane A2 biosynthesis during coronary thrombolysis with intravenous t-PA in patients with acute myocardial infarction. Urinary 2,3-dinor-thromboxane B2, a metabolite of thromboxane A2, was increased to a peak of 3,327 +/- 511 pg/mg creatinine (n = 12) following administration of intravenous t-PA and remained elevated for 48 hours. This increase was abolished by pretreatment with aspirin 325 mg orally (n = 6), indicating de novo biosynthesis of thromboxane A2 rather than washout of preformed metabolites during reperfusion. Prostacyclin (PGI2) biosynthesis, determined by excretion of 2,3-dinor-6-keto-PGF1 alpha, also increased after t-PA administration. However, this increase was less pronounced in patients who reperfused (28 +/- 3.3 ng.hr/mg creatinine) than in patients who failed to reperfuse (118 +/- 30 ng.hr/mg creatinine, p less than 0.05). These data provide evidence of platelet activation during coronary thrombolysis with t-PA. In patients who reperfuse, the reduction in PGI2 biosynthesis may be a marker of reperfusion injury to the vasculature and may further amplify platelet activation.     

Multiple toxicity from 3,4-methylenedioxymethamphetamine ("ecstasy")

There have been no published case series illustrating "ecstasy" (3,4-methylenedioxymethamphetamine [MDMA]) toxicity in a group of patients who have ingested ecstasy in the same environment. We report a series of 7 patients who ingested ecstasy in a nightclub and presented with varying degrees of MDMA toxicity. Three patients presented with features of severe MDMA toxicity. One died within an hour of hospital admission, another died 4 days later, after developing fulminant hepatic failure, and the third recovered after 12 days in intensive care. MDMA was identified in the serum of all 7 patients. High serum MDMA concentrations correlated with severe clinical and biochemical features including coma, hyperpyrexia, cardiovascular compromise, acidosis, and hyperkalaemia. "Poisoned ecstasy" was widely reported by the media as being responsible for the adverse effects observed. This report highlights a relationship between serum concentrations and toxic effects of MDMA, and the ongoing need to educate the public about the dangers of this substance.     

Posterior dislocation of the sternoclavicular joint: a case report and review of the clinical anatomy of the region

Posterior dislocation of the sternoclavicular joint is an uncommon injury. Since 1824, when Sir Astley Cooper described the injury, little more than 100 cases have been described, and the majority of these have been in the last decade, identified by computed tomography. The significant morbidity and mortality associated with this injury is based upon serious damage to important anatomical structures found in the vicinity of the joint. We present a case report, describe the relevant clinical anatomy of this region, and review associated complications.     

A role for cyclooxygenase II inhibitors in modulating temporomandibular joint inflammation from a meal pattern analysis perspective.

PURPOSE: Developing a valid noninvasive animal model to study temporomandibular joint (TMJ) inflammation/pain has proved difficult. However, its has been recently demonstrated that meal pattern analysis, and in particular meal duration, can be used as a biologic marker for TMJ inflammation/pain induced by bilateral injections of complete Freund's adjuvant (CFA). The present study was undertaken to confirm previous findings and extend them by using rofecoxib (VIOXX; Merck and Co, West Point, PA), a selective cyclooxygenase-2 inhibitor (COX-2-I). MATERIALS AND METHODS: Forty-eight male rats were assigned to 1 of 4 groups: group 1, no CFA and no COX-2-I treatment; group 2, no CFA and treatment with the COX-2-I; group 3, bilateral TMJ CFA injection and no COX-2-I treatment; and group 4, CFA injection and treatment with the COX-2-I. Food intake was recorded by computer 24 hours before and for 48 hours after CFA injection. TMJ swelling, chromodacryorrhea, and meal patterns were quantified. RESULTS: CFA increased swelling (P <.05), chromodaccryorrhea (P <.05), meal duration at 24 and 48 hours, and TMJ retrodiscal tissue interleukin-1beta (P < 0.01) in group 3, but treatment with the COX-2-I attenuated these effects in group 4, (CFA + COX-2-I). CONCLUSIONS: These data confirm that meal pattern analysis, and in particular meal duration, is a noninvasive measure of TMJ inflammation/pain. However, this experiment has extended this model as a marker of drug treatment efficacy, specifically the efficacy of COX-2-I in treatment of orofacial inflammation/pain.